STRATEGIC PROPOSAL: THE DE-RISKING FRAMEWORK
I. Pre-Clinical Stress-Testing via DO-Cohort (GDaaS)
Standard C57BL/6 models fail to capture the 유전적(Genetic) variance of the human population. Our Genetic Diversity-as-a-Service (GDaaS) utilizes a massive cohort of Diversity Outbred (DO) mice to stress-test your assets against a spectrum of human-like genetic backgrounds. We provide a high-resolution map of responder/non-responder dynamics, ensuring your clinical trial design is optimized for success.
II. AI-Native Multi-Omics Interrogation
Leveraging our proprietary Lab-AGI and high-throughput multi-omics pipeline (Transcriptomics, Metagenomics, Targeted Metabolomics), we decode the systemic impact of your drug on the Gut-Muscle and Gut-Liver axes. We don’t just report efficacy; we provide the mechanistic proof of target engagement and safety at a resolution that conventional CROs cannot match.
III. Precision Asset Validation & IP Maximization
From TR-FRET-based biophysical binding assays to single-cell RNA sequencing and advanced behavioral phenotyping, we offer a comprehensive suite of validation tools. We help you identify novel biomarkers and refine your IP strategy, transforming raw compounds into de-risked, clinical-ready assets.